Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
- Arroyo González, R.
- Kita, M.
- Crayton, H.
- Havrdova, E.
- Margolin, D.H.
- Lake, S.L.
- Giovannoni, G.
ISSN: 1477-0970, 1352-4585
Year of publication: 2017
Volume: 23
Issue: 10
Pages: 1367-1376
Type: Article